Overview

This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.

Eligibility

Inclusion Criteria:

1. Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer.
2. Planned to undergo definitive chemoradiotherapy ± immunotherapy;
3. Males or females aged 18 to 75;
4. Able to communicate with medical staff.

Exclusion Criteria:

Patients with cognitive impairments.